Nephrology & Internal Medicine. Immunothrombosis incl DIC. ISTH Member. No Conflicts of Interest. Views my own etc
Sydney, Australia
- Tweets 25,061
- Following 3,223
- Followers 32,532
- Likes 124,437
Pinned Tweet
“Death in Hamburg” by @RichardEvans36. A book written in 1987for our COVID age. The title, a reference to Thomas Mann's Death in Venice, this is a review of one of the best books I've ever read. 5/5 stars. 🧵 penguinrandomhouse.com/books…
19
173
486
213,145
RT @BigBadDenis: "Korea makes COVID-19 vaccination part of routine national immunization program"
KDCA says COVID-19 continues producing v…
102
91
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
「もう終わったこと」
「私は大丈夫」
「若い人たちは安全」
「マスクなんて必要ない」
「ただの風邪」
「風土病でしかない」
「子どもは軽症で済む」
コロナを無視することは命に関わります。
作 @YouAreLobbyLud /訳 @OfficeBALES
#第15波ですマスクしましょう😷
💫T.Katsumi@X 🌍🌏🌎
3
6
764
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
A slightly more personal post than usual.
I’ve always believed that scientific disagreement can be discussed without turning into insults, mockery or personal attacks.
Over the last few days, I’ve realised that this seems to have become much harder in some parts of this community.
And honestly, I find that sad.
(1/9) 🧵
17
34
188
12,944
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
The 2026 Amsterdam ISLC-PAIS Conference Abstract Book is now officially online. The Abstract Book is exclusively available to registered in-person attendees. Please log in and visit the Your Access section in the attendee portal to access it.
On behalf of our chair @RobWust we thank all researchers, clinicians, healthcare professionals and experts by experience who submitted their work on Long COVID, ME/CFS and Post-Acute Infection Syndromes (PAIS).
7
6
54
3,997
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
I do believe science can unite safely & accomplish 5 months worth of time into 4 days. Whatever it takes to get this subject matter to the next generation of scientists & doctors who have been encouraged to study #LongCovid.
Ideas are priceless.
Could Mitochondrial Transplantation Open New Research Avenues?
At #ISLCPAIS, Professor @PutrinoLab discusses pioneering research into mitochondrial transplantation, an experimental approach aimed at restoring cellular energy.
#LongCOVIDTheAnswers #longcovid
3
35
153
4,526
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
#ISLCPAIS2026 abstract review.
My thoughts on abstract 2
One of my fav studies which basically replicates @VirusesImmunity bigger studies in transfer of IgG from
patients with #longcovid to mice.
This study provides further evidence for an immune-mediated mechanism of pain in Long COVID, showing that patient-derived IgG targets peripheral sensory neurons in vivo and ex vivo. These findings strengthen the rationale for testing immunomodulatory approaches such as IVIG in carefully designed clinical trials.
Importantly, funding strategies should not focus exclusively on viral persistence: the growing evidence for pathogenic autoantibodies and immune-mediated neuronal dysfunction makes immunomodulation a parallel, high-priority therapeutic avenue that warrants properly powered clinical trials. I’m surprised this is still not on the priority list
3
11
48
3,558
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
ISLC-PAIS 2026 Young Investigator Award
Huge congratulations to Dr. @DaniBeckman on receiving the ISLC-PAIS 2026 Young Investigator Award, recognition of her outstanding research into Long COVID and post-acute infection syndromes.
#ISLCPAIS #LongCOVID #PAIS #MEcfs
4
66
322
11,131
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Thanks to the great team of @aranet_home our production staff can monitor each area of the venue. Here’s the history of today.
3
7
46
3,624
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
We’ve been building this society together for years and today we finally meet in Amsterdam! 🧡
The inaugural ISLC-PAIS Conference starts today with 4 days of science, collaboration and new connections to fight for #LongCOVID and #PAIS.
Welcome to #ISLCPAIS2026! 🔬
@ISLCPAIS
5
9
38
8,936
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Only one week to go until the 2026 Amsterdam ISLC-PAIS Conference brings together more than 300 clinicians, scientists, early-career researchers and patient advocates, all committed to advancing our understanding of Long COVID and other Post-Acute Infection Syndromes.
With more than 100 scientific sessions, the conference will cover the latest research, clinical insights and developments across the field.
To make the key takeaways accessible beyond the conference itself, we are organising the Patient Recap Livestream Session. A dedicated session that translates the most relevant conference insights into clear and accessible information for patients.
islc-pais.org/program/patien…
6
20
754
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Outside a Sydney emergency department this week. Perhaps the penny has dropped that staff keep falling ill and going off sick, and mitigation is possible. Surprising % of patients and staff complying, too.
40
402
1,496
31,169
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Take a front-row seat to the 2026 #Amsterdam ISLC-PAIS Conference with on-demand access to more than 100 recorded scientific and clinical presentations.
At a fraction of the costs, this is the International #LongCOVID #MECFS #PAIS Conference you can attend anytime, whereever you are and at a fraction of the costs.
GET VIDEO ON DEMAND TODAY!
You can miss your peers, but you can't miss out on the latest science.
islc-pais.org/vod
9
25
90
33,167
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
We have family member who has reactivated TB meningitis post covid (several infections). Tuberculoma. Initially diagnosed as brain cancer…so treatment time lost & now terminal.
2
12
45
6,452
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Xocova Tablets 25 mg (Ensitrelvir Fumaric Acid, Shionogi)
ゾコーバ錠25mg（エンシトレルビル フマル酸、塩野義製薬）
ゾコーバはSARS-CoV-2の3CLプロテアーゼを阻害する抗ウイルス薬で、新型コロナウイルス感染症の治療に用いる。
従来は12歳以上の小児と成人に用法・用量が設定されていたが、6月19日に6歳以上かつ体重20kg以上の小児にも対象が拡大された。
25mg錠はこの小児用量への対応に伴う剤形追加で、薬価は1錠2,575.40円。小児加算5％が適用され、薬価維持制度の対象となる。
ピーク時の予測は投与患者278人、販売額0.13億円。
Xocova is a SARS-CoV-2 3CL protease inhibitor for treating COVID-19. Dosing was expanded on June 19 to children aged ≥6 years weighing ≥20 kg, in addition to patients aged ≥12 years. The new 25-mg tablet supports pediatric dosing and is priced at ¥2,575.40 per tablet.
#小児用量 #新型コロナウイルス感染症 #3CLプロテアーゼ阻害剤
#PediatricDosing #COVID19 #3CLProteaseInhibitor
mixonline.jp/tabid55.html?ar…
At last, a pill that can prevent COVID after exposure to infected people
感染者との接触後にCOVID-19を防ぐ初の飲み薬
抗ウイルス薬エンシトレルビル（ゾコーバ）が、家庭内でSARS-CoV-2に暴露した人のCOVID-19発症を防ぐ可能性を示した。
2,000人超を対象にした国際試験では、同居人の発症から72時間以内に5日間服用した人の発症率は約3%で、プラセボ群の約9%より低かった。
感染そのものも、エンシトレルビル群で14.0%、プラセボ群で21.5%と少なかった。忍容性はおおむね良好だった。
日本では曝露後予防として承認されており、高齢者、基礎疾患のある人、免疫抑制中の人、医療従事者などで有用性が期待される。
Ensitrelvir, marketed as Xocova, is the first antiviral pill shown to prevent COVID-19 after household exposure. In a trial of more than 2,000 contacts, five days of treatment within 72 hours cut symptomatic illness from about 9% to 3%. It may help protect people at high risk.
nature.com/articles/d41586-0…
#COVID19 #エンシトレルビル #曝露後予防
#COVID19 #ensitrelvir #postexposureprophylaxis
1
8
17
3,539
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Dear @RobWust and everyone at @ISLCPAIS
Please do not get discouraged by some of the unnecessary, rude, or downright stupid posts here, hating on every little detail they do not like about your work.
The vast majority of patients are beyond grateful for what you are doing! 🙏
5
16
190
6,328